Subscribe to Print Edition | Wed., March 25, 2009 Adar 29, 5769 | | Israel Time: 18:42 (EST+7)
Haaretz israel news English
web haaretz.com
Haaretz Toolbar
Diplomacy
Defense Jewish World Opinion National
Print Edition
Car Rental
Books Haaretz Magazine Business Real Estate Joy of Giving Travel Week's End Anglo File
Last update - 10:35 09/12/2008
An ultra-Orthodox startup's secret to weathering crises: modest living
By Guy Grimland, TheMarker Correspondent
Tags: Jewish world, israel news 

Startups up and down the land are slashing at salaries and perks as the financial crisis bites down, threatening their very survival. But there's one company that doesn't need to cut to the bone.

Immune System Key doesn't need to take any special steps to weather the world crisis because its workers only make NIS 4,000 a month to begin with. They don't drive company cars or take taxis, but ride the bus to work. They never fly abroad, at least not on "company business." Life at the office is characterized not by voucher lunches at local eateries, but by reserve and restraint.

The man behind this model of modesty is Dr. Yoram Devary, scientist and "the first ultra-Orthodox entrepreneur." His startup employs nine people, all Haredim.
Advertisement
ISK's offices are located at the Cardiac Institute of the Jerusalem College of Technology. The office space is segregated by gender, with one area earmarked for men and another area for women, as befits the mores of the ultra-Orthodox community. The company's staff includes two women, one Devary's wife, an endocrinologist, and the other her assistant.

ISK, formerly known as ThymoFight, is working on drug development for treatment of cancers and autoimmune diseases such as Crohn's, using a proprietary peptide chain (a piece of protein) - more on that below. The peptide has been named "Nerofe," which is based on the Hebrew word for "cure."

So far the company has taken in $1,400,000 in support from the Chief Scientist of the Ministry of Industry and Trade, in two payments of $700,000 each, and has raised "a lot" from private sector investors.

Devary doesn't think he's ready to approach venture capitalists just yet, not that the world's venture capitalists are in a mood to scatter money around these days.

"I want to go to them from a position of strength," he explains. "Anyway, why should I give 50% of the ownership in the company to somebody else?"

Working on a tight budget, ISK "thinks twice" before embarking on any experiment, Devary says. "The fact that we don't have money is a big advantage. The more money there is, the greater the confusion, and it goes the other way around. That's why the present crisis isn't affecting us."

Devary's personal story is not the usual one of an Israeli "start-upist." He found religion 27 years ago, at the age of 18, after meeting his future wife at a science workshop at the Weizmann Institute of Science.

"She was religious and I was secular," he relates. They lost touch for a while but then reconnected and wound up marrying. "She influenced me to become religious," he says.

He completed not one but two bachelor's degrees at the Hebrew University of Jerusalem, in biology and in chemistry, then studied at the San Diego School of Medicine, at the San Diego campus of the University of California, where he received his doctorate in basic medical sciences.

Not satisfied with his academic achievements yet, Devary then studied computer science in his spare time, while teaching and conducting research at the Jerusalem College of Technology. In 1999 he was tapped to found the bioinformatics department at the Cardiac Institute and come 2005, the Cardiac Institute received licensing to launch an academic program for the logical planning of pharmaceuticals.

The year before, Devary took part in a seminar at Tel Aviv University together with a fellow scientist, Prof. Azriel Sandler. The seminar was about the discovery of new hormones consisting of peptides (protein chains). Insulin, which regulates the level of sugar in the blood, is one example of a peptide hormone.

Devary left the seminar feeling dissatisfied. Insulin is made by the pancreas, and when its production goes haywire for whatever reason, diabetes results. Devary wondered why no single drug similar in potential to insulin had been discovered in the last 10 years, even though oceans of money had been poured into the search.

"From about 1994 or 1995 to 2004, some $4 billion had been put into finding new peptide hormones, but the result was beigeleh," he says, or, zilch.

"It turned out that science's ability to discover new peptide hormones was limited," he relates. "We left the seminar feeling irritated, and for a year played around with the idea of finding a new way to discover peptide hormones."

Then came a eureka moment that led to the discovery of a genetic sequence, which might, might just be a peptide hormone on chromosome 10.

Humans have 46 chromosomes, in 23 pairs, and for all the hype surrounding genetic engineering and the revival of the woolly mammoth, scientists are far from understanding how our genetic material - DNA - actually works. Research continues apace, however, and in the case of ISK, the discovery was a "virtual" one, Devary explains - an "intelligent guess" based on better use of existing computerized tools.

They were pleased with the discovery, he says, but didn't actually do anything about it.

Until his wife became involved, that is.

"She heard the conversations and asked why we weren't checking the discovery physically. Perhaps a peptide with medical abilities could be produced," he says. "Finally we decided to check it out in depth. I used my own money and bought a PCR device." That's shorthand for "DNA polymerase chain reaction" machine.

What the DNA polymerase chain reaction machine does is replicate a piece of DNA, using enzymes. That DNA then serves as a template for protein production.

The long and short of it is that the genetic sequence they'd discovered becomes a protein that is expressed in the thyroid gland, which is responsible for the development of the body's immune system.

The thyroid is also "responsible" for the development of autoimmune system diseases, which is when the immune system goes awry, overreacts and attacks the body. Examples include multiple sclerosis, Addison's disease, another is celiac disease.

Discovering that the peptide was involved in immune system development was crucial. Devary and Sandler obtained $100,000 from private investors and family members, and began clinical trials on animals. They found that the peptide was efficient in helping to treat Crohn's Disease, which attacks the intestines, and various conditions of the blood, including leukemia.

So far ISK has registered five patents on its pet peptide, based on its uses. Now Devary intends to take the company to the next stage, though the team has yet to decide which direction to go in - toward Crohn's or leukemia. Meanwhile, Ichilov Hospital, at the Tel Aviv Medical Center, has granted permission for human clinical trials of the peptide for diagnostic purposes. More specifically, the peptide is being tested for two roles: to detect early-stage leukemia, when it's easier to treat, and to detect people with a heightened tendency to develop the disease, Devary explains.

Devary may not want venture capital at this stage, but he does mean to find investors to provide $1.5 million to $2 million. And no, he doesn't mean to use that money to raise salaries.

Related articles:
  • Hard times hit high-tech Anglos
  • U.S. entrepreneur makes aliyah seeking 'next big invention'
  • Study: 25,000 high-tech workers left for U.S. in last seven years
    • Bookmark to del.icio.us  
     
    Military in denial
    IDF chief Ashkenazi refuses to believe IDF troops harmed Gaza civilians in cold blood.
    Coalitional contention
    Labor demands chairmanship of key Knesset committee promised to Lieberman.
      1.   Thyroid or thymus? 09:23  |  Aaron 09/12/08
      2.   Not the first 09:54  |  Ken 09/12/08
      3.   Thyroid or Thymus 10:08  |  Bio 09/12/08
      4.   Why do non-family skilled workers they accept minimum wage? 11:43  |  Frank Markos 09/12/08
      5.   Finally, a non-greedy person. B`hatslakha! 12:05  |  Dan 09/12/08
      6.   4000 NIS is welfare, not a wage 12:50  |  Josh B 09/12/08
      7.   4000? 13:05  |  k 09/12/08
      8.   ISK 14:03  |  DRUG 09/12/08
      9.   "modesty"=below-market salary? 14:40  |  Susan 09/12/08
      10.   ISK 15:17  |  Mark 09/12/08
      11.   All the best to ISK but... 15:34  |  Hastaroth 09/12/08
      12.   The babysitter makes more than that 15:46  |  Rina 09/12/08
      13.   How dare they work for so little and do such good work 15:49  |  Allon 09/12/08
      14.   If I recall Stef Wertheimer . . . 16:02  |  Zev Davis9 09/12/08
      15.   MOTIVATION OF RELIGIOUS PEOPLE BEYOND IMAGINATION!)))) 16:10  |  VOICE of MOSHIACH))) 09/12/08
      16.   Prudent, sensible and intelligent 21:55  |  Mark Lincoln 09/12/08
      17.   Susan - have you ever started a business 22:11  |  Mark Lincoln 09/12/08
      18.   The Peptid, Nerofe, for Crohn`s patient 18:57  |  Jackie Shahar 23/03/09
     Haaretz Hot Topics
    Israel 2009 election results: Voter breakdown
    Israel goes to the polls
    Conflict in Gaza
    Israel vs. Hamas
    Iran: Nuclear and regional ambitions
    More Headlines
    17:15 MI chief: Iran has crossed nuclear bomb threshold
    17:16 Assad says Syria-Israel talks depend on clear U.S. position
    15:18 Netanyahu: I will hold peace talks with Palestinian Authority
    18:36 Rights group: Gaza inmate tortured to death by Hamas security
    18:02 IDF soldier hurt in Jordan Valley shooting-range accident
    16:47 6 Danes convicted of selling T-shirts to fund Palestinian terror
    18:35 Rights group: Israel made illegal use of phosphorus shells in Gaza
    23:11 WATCH: Daily news round-up from Israel
    17:12 Mother of slain French Jew Ilan Halimi calls for public trial
    15:26 Israeli stars fall prey to comic's conman brother
    11:22 IDF: 600 Hamas men, 309 civilians died in Gaza offensive
    15:02 Labor split over entry to Netanyahu coalition
    11:45 Palestinians use Animal Farm play to criticize local politics
    13:38 Netanyahu, Lieberman 'struck secret deal for West Bank construction'
    Previous Editions
    Special Offers
    Advertisement
    Spring Specials-Dan Hotels
    Jerusalem from 179$. Tel-Aviv from 223$. Herzliya from 336$
    Dead Sea Skin Care
    Quality cosmetics from the Dead Sea. Coupon code HAARETZ for 12% off!
    Camp Kimama Israel 2009
    The best place for your children this summer
    Eldan Rent a Car
    Israel's leading car rental company offers you a 20% discount on online reservations
    Jewish Singles Personal Ads
    Find the love of your life on JDate.com
    Junkyard
    Junk a car - get free towing nationwide and a tax-deductible receipt
    Home | TV | Print Edition | Diplomacy | Opinion | Arts & Leisure | Sports | Jewish World | | Israel 2009 election results
    Site rules | Makom: Engaging on Israel | Search engine marketing
    Haaretz.com, the online edition of Haaretz Newspaper in Israel, offers real-time breaking news, opinions and analysis from Israel and the Middle East. Haaretz.com provides extensive and in-depth coverage of Israel, the Jewish World and the Middle East, including defense, diplomacy, the Arab-Israeli conflict, the peace process, Israeli politics, Jerusalem affairs, international relations, Iran, Iraq, Syria, Lebanon, the Palestinian Authority, the West Bank and the Gaza Strip, the Israeli business world and Jewish life in Israel and the Diaspora.
    © Copyright  Haaretz. All rights reserved